{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:16:55Z","timestamp":1784740615903,"version":"3.55.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Isr J Health Policy Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>New vaccines and monoclonal antibody (mAb) against respiratory syncytial virus (RSV) were recently approved for adults and infants, respectively. However, their inclusion in national vaccination programs has been slow. Accurate assessment of RSV disease burden among all ages is essential for the global introduction of these agents. <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We evaluated all-ages burden of RSV hospitalizations, from 2020 to 2024, based on data collected by a new national laboratory-based hospital surveillance system. RSV-positive respiratory samples from patients hospitalized in general hospitals nationwide were reported. Data were analyzed by RSV circulation periods and age-group to determine hospitalization rates and 30-day mortality (30-DM) rates.\u00a0We compared the laboratory-confirmed hospitalization rates with rates previously calculated based on ICD-9 codes. <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>RSV-confirmed hospitalizations were reported for all age-groups. The highest RSV hospitalization rates were found among patients\u2009&lt;\u20091\u00a0year old. Patients\u2009\u2265\u200960\u00a0years old had the highest RSV hospitalization rates among\u2009\u2265\u20095\u00a0years old patients, and their 30-DM rates reached 14.7%, exceeding those of influenza. During the COVID-19 pandemic, lower rates of RSV-confirmed hospitalizations were reported among\u2009\u2265\u200960\u00a0years old patients, probably due to higher adherence to social distancing measures. We found higher numbers and rates of laboratory-confirmed hospitalizations among all age-groups\u2009\u2265\u20091\u00a0year old, than those previously reported by our group, based on ICD-9 codes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Laboratory-confirmation of RSV is paramount for optimal assessment of RSV hospitalization burden, particularly beyond infancy, and for the global adoption of newly developed vaccines and mAb.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13584-025-00693-5","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T06:22:12Z","timestamp":1749622932000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Laboratory-confirmed respiratory syncytial virus (RSV) hospitalizations: a national all ages cross-section evaluation, 2020\u20132024"],"prefix":"10.1186","volume":"14","author":[{"given":"Aharona","family":"Glatman-Freedman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Gur-Arie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Dichtiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lital","family":"Keinan-Boker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Bromberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"with the Israeli Respiratory Viruses Hospital Laboratory Network (IRVHLN)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"key":"693_CR1","unstructured":"U.S. Food and Drug Administration. Respiratory Syncytial Virus (RSV). FDA has approved vaccines and monoclonal antibodies to protect against RSV. 2024. https:\/\/www.fda.gov\/consumers\/covid-19-flu-and-rsv\/respiratory-syncytial-virus-rsv 2024 [updated 22 October 2024; cited 12 February 2025]."},{"key":"693_CR2","unstructured":"European Medicines Agency. RSV. 2025. https:\/\/www.ema.europa.eu\/en\/search?search_api_fulltext=RSV&f%5B0%5D=ema_search_entity_is_document%3ADocument 2025 [updated 9 January 2025; cited 12 February 2025]."},{"issue":"9","key":"693_CR3","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1056\/NEJMoa2110275","volume":"386","author":"LL Hammitt","year":"2022","unstructured":"Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386(9):837\u201346.","journal-title":"N Engl J Med"},{"key":"693_CR4","doi-asserted-by":"publisher","first-page":"e2024067174","DOI":"10.1542\/peds.2024-067174","volume":"154","author":"D Wilkins","year":"2024","unstructured":"Wilkins D, W\u00e4hlby-Hamr\u00e9n U, Chang Y, Clegg LE, Domachowske J, Englund JA, et al. RSV neutralizing antibodies following nirsevimab and palivizumab dosing. Pediatrics. 2024;154:e2024067174.","journal-title":"Pediatrics"},{"issue":"6","key":"693_CR5","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3390\/vaccines12060640","volume":"12","author":"M Ricc\u00f2","year":"2024","unstructured":"Ricc\u00f2 M, Cascio A, Corrado S, Bottazzoli M, Marchesi F, Gili R, et al. Impact of nirsevimab immunization on pediatric hospitalization rates: a systematic review and meta-analysis. Vaccines. 2024;12(6):640.","journal-title":"Vaccines"},{"key":"693_CR6","unstructured":"Israel Ministry of Health. The Public Committee for the Expansion of the Healthcare Services Basket for the Year 2025 Concluded Discussions and Submitted Its Recommendations to the Minister of Health. 6 February 2025. https:\/\/www.gov.il\/en\/pages\/06022025-01. 2025."},{"key":"693_CR7","unstructured":"UK department of Health and Social care. National RSV vaccination programme announced. 17 July 2024. https:\/\/www.gov.uk\/government\/news\/national-rsv-vaccination-programme-announced [press release]. 2024."},{"key":"693_CR8","unstructured":"Government of Canada. Respiratory syncytial virus (RSV) vaccines: Canadian Immunization Guide. 6 November 2024. https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/respiratory-syncytial-virus.html. 2024."},{"key":"693_CR9","unstructured":"Australian government. Department of Health and Aged Care. National Immunisation Program update\u2014RSV vaccine. 10 November 2024 https:\/\/www.health.gov.au\/news\/national-immunisation-program-update-rsv-vaccine [press release]. 2024."},{"key":"693_CR10","unstructured":"Medicare interactive. Part D-covered vaccinations; 2024. https:\/\/www.medicareinteractive.org\/get-answers\/medicare-prescription-drug-coverage-part-d\/medicare-part-d-costs\/part-d-covered-vaccinations."},{"key":"693_CR11","unstructured":"World Health Organization. WHO Global Market Study on respiratory syncytial virus immunization products. November 2024. https:\/\/cdn.who.int\/media\/docs\/default-source\/immunization\/mi4a\/who-global-market-study-on-rsv-immunization-products_november-2024.pdf?sfvrsn=e6ff42a9_3&download=true. 2024."},{"issue":"10","key":"693_CR12","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S2213-2600(24)00255-8","volume":"12","author":"JG Wildenbeest","year":"2024","unstructured":"Wildenbeest JG, Lowe DM, Standing JF, Butler CC. Respiratory syncytial virus infections in adults: a narrative review. Lancet Respir Med. 2024;12(10):822\u201336.","journal-title":"Lancet Respir Med"},{"issue":"32","key":"693_CR13","doi-asserted-by":"publisher","first-page":"2300634","DOI":"10.2807\/1560-7917.ES.2024.29.32.2300634","volume":"29","author":"L Gur-Arie","year":"2024","unstructured":"Gur-Arie L, Stein M, Sefty H, Fratty IS, Nemet I, Kliker L, et al. Hospital surveillance of respiratory viruses during the COVID-19 pandemic and beyond: contribution to the WHO mosaic framework, Israel, 2020 to 2023. Eurosurveillance. 2024;29(32):2300634.","journal-title":"Eurosurveillance"},{"issue":"2","key":"693_CR14","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jinf.2020.05.078","volume":"81","author":"A Glatman-Freedman","year":"2020","unstructured":"Glatman-Freedman A, Kaufman Z, Applbaum Y, Dichtiar R, Steiman A, Gordon ES, et al. Respiratory Syncytial Virus hospitalization burden: a nation-wide population-based analysis, 2000\u20132017. J Infect. 2020;81(2):297\u2013303.","journal-title":"J Infect"},{"key":"693_CR15","unstructured":"Israel Central Bureau of Statistics. Population\u2014Statistical Abstract of Israel 2023\u2014No.74. 2023 [17 October 2024]. Available from: https:\/\/www.cbs.gov.il\/en\/publications\/Pages\/2023\/Population-Statistical-Abstract-of-Israel-202-No-74.aspx."},{"issue":"1","key":"693_CR16","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3390\/microorganisms11010166","volume":"11","author":"Y Oster","year":"2023","unstructured":"Oster Y, Abu Ahmad W, Michael-Gayego A, Rivkin M, Levinzon L, Wolf D, et al. Viral and bacterial respiratory pathogens during the COVID-19 pandemic in Israel. Microorganisms. 2023;11(1):166.","journal-title":"Microorganisms"},{"key":"693_CR17","unstructured":"Israel Ministry of Health. \u201cGreen Pass\u201d and \u201cPurple Badge\u201d Guidance and Gathering Restrictions Effective 18.8.2021. [press release]. 15 August 2021. https:\/\/www.gov.il\/en\/pages\/15082021-02. 2021."},{"key":"693_CR18","unstructured":"Israel Ministry of Health. The Coronavirus Cabinet Approved the Prime Minister and the Minister of Health Bills for Coping with the New \u201cOmicron\u201d Variant [press release]. 27 November 2021. https:\/\/www.gov.il\/en\/pages\/27112021-03. 2021."},{"key":"693_CR19","unstructured":"Israel Center for Disease Control. Israel respiratory viruses report. Week 17 2024. 27 April 2024. https:\/\/www.gov.il\/en\/pages\/flu-27042024. 2024."},{"key":"693_CR20","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2147\/CLEP.S485953","volume":"16","author":"CY Hsieh","year":"2024","unstructured":"Hsieh CY, Chen PT, Shao SC, Lin SJ, Liao SC, Lai EC. Validating ICD-10 diagnosis codes for Guillain\u2013Barr\u00e9 syndrome in Taiwan\u2019s National Health insurance claims database. Clin Epidemiol. 2024;16:733\u201342.","journal-title":"Clin Epidemiol"},{"issue":"1","key":"693_CR21","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1186\/s12911-024-02724-8","volume":"24","author":"E Gabel","year":"2024","unstructured":"Gabel E, Gal J, Grogan T, Hofer I. A retrospective analysis using comorbidity detecting algorithmic software to determine the incidence of International Classification of Diseases (ICD) code omissions and appropriateness of Diagnosis-Related Group (DRG) code modifiers. BMC Med Inform Decis Mak. 2024;24(1):309.","journal-title":"BMC Med Inform Decis Mak"},{"issue":"12","key":"693_CR22","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.1016\/j.arth.2021.08.002","volume":"36","author":"EA Chen","year":"2021","unstructured":"Chen EA, Roof MA, Lygrisse KA, Kurapatti M, Hepinstall MS, Schwarzkopf R. ICD-10 coding mismatch in computer and robotic assisted primary total hip arthroplasty. J Arthroplasty. 2021;36(12):3934\u20137.","journal-title":"J Arthroplasty"},{"issue":"1","key":"693_CR23","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12911-021-01531-9","volume":"21","author":"N Wabe","year":"2021","unstructured":"Wabe N, Li L, Lindeman R, Post JJ, Dahm MR, Li J, et al. Evaluation of the accuracy of diagnostic coding for influenza compared to laboratory results: the availability of test results before hospital discharge facilitates improved coding accuracy. BMC Med Inform Decis Mak. 2021;21(1):168.","journal-title":"BMC Med Inform Decis Mak"},{"issue":"Supplement_1","key":"693_CR24","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1093\/infdis\/jiad415","volume":"229","author":"AM Egeskov-Cavling","year":"2024","unstructured":"Egeskov-Cavling AM, Johannesen CK, Lindegaard B, Fischer TK. Underreporting and misclassification of respiratory syncytial virus-coded hospitalization among adults in Denmark between 2015\u20132016 and 2017\u20132018. J Infect Dis. 2024;229(Supplement_1):S78\u201383.","journal-title":"J Infect Dis"},{"key":"693_CR25","doi-asserted-by":"publisher","first-page":"111568","DOI":"10.1016\/j.forsciint.2023.111568","volume":"343","author":"P Pinto Pastor","year":"2023","unstructured":"Pinto Pastor P, Dorado Fern\u00e1ndez E, Albarr\u00e1n Juan E, Santiago-S\u00e1ez A. Quality analysis of the completion of death certificates in Madrid. Forensic Sci Int. 2023;343:111568.","journal-title":"Forensic Sci Int"},{"key":"693_CR26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.lungcan.2019.05.016","volume":"134","author":"KS Tan","year":"2019","unstructured":"Tan KS. Misclassification of the actual causes of death and its impact on analysis: a case study in non-small cell lung cancer. Lung Cancer. 2019;134:16\u201324.","journal-title":"Lung Cancer"},{"issue":"10","key":"693_CR27","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.2105\/AJPH.2017.303940","volume":"107","author":"JM Feldman","year":"2017","unstructured":"Feldman JM, Gruskin S, Coull BA, Krieger N. Killed by police: validity of media-based data and misclassification of death certificates in Massachusetts, 2004\u20132016. Am J Public Health. 2017;107(10):1624\u20136.","journal-title":"Am J Public Health"},{"issue":"5","key":"693_CR28","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1177\/0033354918782494","volume":"133","author":"OC Tran","year":"2018","unstructured":"Tran OC, Lucero DE, Balter S, Fitzhenry R, Huynh M, Varma JK, et al. Sensitivity and positive predictive value of death certificate data among deaths caused by Legionnaires\u2019 disease in New York City, 2008\u20132013. Public Health Rep. 2018;133(5):578\u201383.","journal-title":"Public Health Rep"},{"issue":"1","key":"693_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13690-021-00637-w","volume":"79","author":"H Izci","year":"2021","unstructured":"Izci H, Tambuyzer T, Vandeven J, Xicluna J, Wildiers H, Punie K, et al. Cause of death for patients with breast cancer: discordance between death certificates and medical files, and impact on survival estimates. Arch Public Health. 2021;79(1):111.","journal-title":"Arch Public Health"},{"issue":"5","key":"693_CR30","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1002\/ijc.32887","volume":"147","author":"B French","year":"2020","unstructured":"French B, Sadakane A, Cologne J, Mabuchi K, Ozasa K, Preston DL. Misclassification of primary liver cancer in the Life Span Study of atomic bomb survivors. Int J Cancer. 2020;147(5):1294\u20139.","journal-title":"Int J Cancer"},{"key":"693_CR31","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.canep.2019.02.004","volume":"59","author":"MD Wissing","year":"2019","unstructured":"Wissing MD, Greenwald ZR, Franco EL. Improving the reporting of cancer-specific mortality and survival in research using cancer registry data. Cancer Epidemiol. 2019;59:232\u20135.","journal-title":"Cancer Epidemiol"},{"issue":"4","key":"693_CR32","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1080\/23744235.2025.2450590","volume":"57","author":"N Inoue","year":"2025","unstructured":"Inoue N, Nagai H, Fushimi K. Severity and outcomes of adult respiratory syncytial virus inpatient compared with influenza: observational study from Japan. Infect Dis (Lond). 2025;57(4):366\u201375.","journal-title":"Infect Dis (Lond)"},{"issue":"10","key":"693_CR33","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1097\/INF.0000000000004038","volume":"42","author":"N Bouckaert","year":"2023","unstructured":"Bouckaert N, Lef\u00e8vre M, Van den Heede K, Van de Voorde C. RSV burden and its impact on pediatric inpatient bed occupancy in Belgium: an analysis of national hospital claims data. Pediatr Infect Dis J. 2023;42(10):857\u201361.","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"693_CR34","doi-asserted-by":"publisher","first-page":"26","DOI":"10.14745\/ccdr.v51i01a04","volume":"51","author":"EM Abrams","year":"2025","unstructured":"Abrams EM, Doyon-Plourde P, Davis P, Lee L, Rahal A, Brousseau N, et al. Burden of disease of respiratory syncytial virus in older adults and adults considered at high risk of severe infection. Can Commun Dis Rep. 2025;51(1):26\u201334.","journal-title":"Can Commun Dis Rep"},{"key":"693_CR35","doi-asserted-by":"publisher","first-page":"1377968","DOI":"10.3389\/fpubh.2024.1377968","volume":"12","author":"A Ciapponi","year":"2024","unstructured":"Ciapponi A, Palermo MC, Sandoval MM, Baumeister E, Ruvinsky S, Ulloa-Gutierrez R, et al. Respiratory syncytial virus disease burden in children and adults from Latin America: a systematic review and meta-analysis. Front Public Health. 2024;12:1377968.","journal-title":"Front Public Health"},{"issue":"39","key":"693_CR36","doi-asserted-by":"publisher","first-page":"2400119","DOI":"10.2807\/1560-7917.ES.2024.29.39.2400119","volume":"29","author":"M Stucki","year":"2024","unstructured":"Stucki M, Lenzin G, Agyeman PK, Posfay-Barbe KM, Ritz N, Tr\u00fcck J, et al. Inpatient burden of respiratory syncytial virus (RSV) in Switzerland, 2003 to 2021: an analysis of administrative data. Euro Surveill. 2024;29(39):2400119.","journal-title":"Euro Surveill."},{"issue":"1","key":"693_CR37","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1186\/s12879-024-09758-3","volume":"24","author":"A Poshtiban","year":"2024","unstructured":"Poshtiban A, Wick M, Bangert M, Damm O. Burden of respiratory syncytial virus (RSV) infection in Germany: a systematic review. BMC Infect Dis. 2024;24(1):844.","journal-title":"BMC Infect Dis"},{"issue":"10","key":"693_CR38","doi-asserted-by":"publisher","first-page":"e2336863","DOI":"10.1001\/jamanetworkopen.2023.36863","volume":"6","author":"M Bourdeau","year":"2023","unstructured":"Bourdeau M, Vadlamudi NK, Bastien N, Embree J, Halperin SA, Jadavji T, et al. Pediatric RSV-associated hospitalizations before and during the COVID-19 pandemic. JAMA Netw Open. 2023;6(10):e2336863.","journal-title":"JAMA Netw Open"},{"issue":"11","key":"693_CR39","doi-asserted-by":"publisher","first-page":"e70006","DOI":"10.1002\/jmv.70006","volume":"96","author":"O Fl\u00e9chelles","year":"2024","unstructured":"Fl\u00e9chelles O, Oger C, Charollais A, Drame M, Banydeen R, Najioullah F. Burden and seasonality of RSV bronchiolitis in hospitalized children on a French Caribbean island: practical lessons from a 13-year study. J Med Virol. 2024;96(11):e70006.","journal-title":"J Med Virol"},{"key":"693_CR40","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ajem.2024.11.002","volume":"87","author":"SI Masoom","year":"2024","unstructured":"Masoom SI, Aloisio G, Camp EA, Dunn JJ, Meskill SD. Characterizing respiratory syncytial virus (RSV) infections before and during the COVID-19 pandemic. Am J Emerg Med. 2024;87:108\u201312.","journal-title":"Am J Emerg Med"},{"issue":"11","key":"693_CR41","doi-asserted-by":"publisher","first-page":"e70046","DOI":"10.1111\/irv.70046","volume":"18","author":"G Sever Yildiz","year":"2024","unstructured":"Sever Yildiz G, Resch E, Strenger V, Eber E, Resch B. Evaluating the economic and epidemiological impact of RSV hospitalizations in Southern Austria [Southern Austria Respiratory Syncytial Virus INpatient Investigation (ARNI Study)]. Influenza Other Respir Viruses. 2024;18(11):e70046.","journal-title":"Influenza Other Respir Viruses"},{"issue":"11","key":"693_CR42","doi-asserted-by":"publisher","first-page":"e2444756","DOI":"10.1001\/jamanetworkopen.2024.44756","volume":"7","author":"FP Havers","year":"2024","unstructured":"Havers FP, Whitaker M, Melgar M, Pham H, Chai SJ, Austin E, et al. Burden of respiratory syncytial virus-associated hospitalizations in US adults, October 2016 to September 2023. JAMA Netw Open. 2024;7(11):e2444756.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"693_CR43","doi-asserted-by":"publisher","first-page":"e830","DOI":"10.1093\/infdis\/jiaf056","volume":"231","author":"A Urchuegu\u00eda-Fornes","year":"2025","unstructured":"Urchuegu\u00eda-Fornes A, Mu\u00f1oz-Quiles C, Mira-Iglesias A, L\u00f3pez-Lacort M, Mengual-Chuli\u00e1 B, L\u00f3pez-Labrador FX, et al. Ten-year surveillance of RSV hospitalizations in adults: incidence rates and case definition implications. J Infect Dis. 2025;231(5):e830\u20139.","journal-title":"J Infect Dis."},{"issue":"9","key":"693_CR44","doi-asserted-by":"publisher","first-page":"750","DOI":"10.3390\/pathogens13090750","volume":"13","author":"T Brosh-Nissimov","year":"2024","unstructured":"Brosh-Nissimov T, Ostrovsky D, Cahan A, Maaravi N, Leshin-Carmel D, Burrack N, et al. Adult respiratory syncytial virus infection: defining incidence, risk factors for hospitalization, and poor outcomes, a regional cohort study, 2016\u20132022. Pathogens. 2024;13(9):750.","journal-title":"Pathogens"},{"key":"693_CR45","first-page":"101221","volume":"51","author":"D Broderick","year":"2024","unstructured":"Broderick D, Cheung I, Paynter J, O\u2019Donnell J, Albrecht S, Aminisani N, et al. RSV severity in New Zealand 2021 and 2022: applying the WHO severity assessment framework. Lancet Reg Health West Pac. 2024;51:101221.","journal-title":"Lancet Reg Health West Pac"},{"key":"693_CR46","unstructured":"Israel Ministry of Health. List of medicines and medical foods submitted for the 2025 healthcare services basket committee [Hebrew]; 2025. https:\/\/www.gov.il\/BlobFolder\/reports\/hbs2025\/he\/files_committees_hbs_2025_List-of-medicines-and-medical-food-2025.pdf. Cited 1 May 2025."},{"issue":"1","key":"693_CR47","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40121-021-00566-9","volume":"11","author":"N Voirin","year":"2022","unstructured":"Voirin N, Virlogeux V, Demont C, Kieffer A. Potential impact of nirsevimab on RSV transmission and medically attended lower respiratory tract illness caused by RSV: a disease transmission model. Infect Dis Therapy. 2022;11(1):277\u201392.","journal-title":"Infect Dis Therapy"},{"issue":"2","key":"693_CR48","doi-asserted-by":"publisher","first-page":"100320","DOI":"10.1016\/j.opresp.2024.100320","volume":"6","author":"I Sanz-Mu\u00f1oz","year":"2024","unstructured":"Sanz-Mu\u00f1oz I, Castrodeza-Sanz J, Eiros JM. Potential effects on elderly people from nirsevimab use in infants. Open Respir Arch. 2024;6(2):100320.","journal-title":"Open Respir Arch"},{"issue":"14","key":"693_CR49","doi-asserted-by":"publisher","first-page":"2400637","DOI":"10.2807\/1560-7917.ES.2025.30.14.2400637","volume":"30","author":"F Menegale","year":"2025","unstructured":"Menegale F, Vezzosi L, Tirani M, Scarioni S, Odelli S, Morani F, et al. Impact of routine prophylaxis with monoclonal antibodies and maternal immunisation to prevent respiratory syncytial virus hospitalisations, Lombardy region, Italy, 2024\/25 season. Euro Surveill. 2025;30(14):2400637.","journal-title":"Euro Surveill."},{"key":"693_CR50","doi-asserted-by":"crossref","unstructured":"Cox SN, Roychoudhury P, Frivold C, Acker Z, Babu TM, Boisvert CL, et al. Household transmission and genomic diversity of respiratory syncytial virus (RSV) in the United States, 2022\u20132023. Clinical infectious diseases. 2025. Online ahead of print.","DOI":"10.1093\/cid\/ciaf048"},{"key":"693_CR51","unstructured":"World Happiness Report 2024. Appendix 1: Statistical appendix for chapter 2 of World Happiness Report. https:\/\/happiness-report.s3.amazonaws.com\/2024\/Ch2+Appendix.pdf. 2024."},{"issue":"8","key":"693_CR52","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S1473-3099(24)00215-9","volume":"24","author":"S Ares-G\u00f3mez","year":"2024","unstructured":"Ares-G\u00f3mez S, Mallah N, Santiago-P\u00e9rez MI, Pardo-Seco J, P\u00e9rez-Mart\u00ednez O, Otero-Barr\u00f3s MT, et al. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study. Lancet Infect Dis. 2024;24(8):817\u201328.","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"693_CR53","doi-asserted-by":"publisher","first-page":"209","DOI":"10.15585\/mmwr.mm7309a4","volume":"73","author":"HL Moline","year":"2024","unstructured":"Moline HL, Tannis A, Toepfer AP, Williams JV, Boom JA, Englund JA, et al. Early estimate of nirsevimab effectiveness for prevention of respiratory syncytial virus-associated hospitalization among infants entering their first respiratory syncytial virus season\u2014new vaccine surveillance network, October 2023\u2013February 2024. MMWR Morb Mortal Wkly Rep. 2024;73(9):209\u201314.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10","key":"693_CR54","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/S2352-4642(24)00171-8","volume":"8","author":"R Carbajal","year":"2024","unstructured":"Carbajal R, Boelle PY, Pham A, Chazette Y, Schellenberger M, Weil C, et al. Real-world effectiveness of nirsevimab immunisation against bronchiolitis in infants: a case-control study in Paris, France. Lancet Child Adolesc Health. 2024;8(10):730\u20139.","journal-title":"Lancet Child Adolesc Health"},{"issue":"3","key":"693_CR55","doi-asserted-by":"publisher","first-page":"e250380","DOI":"10.1001\/jamanetworkopen.2025.0380","volume":"8","author":"H Xu","year":"2025","unstructured":"Xu H, Aparicio C, Wats A, Araujo BL, Pitzer VE, Warren JL, et al. Estimated effectiveness of nirsevimab against respiratory syncytial virus. JAMA Netw Open. 2025;8(3):e250380.","journal-title":"JAMA Netw Open."},{"issue":"12","key":"693_CR56","doi-asserted-by":"publisher","first-page":"e2450832","DOI":"10.1001\/jamanetworkopen.2024.50832","volume":"7","author":"SY Tartof","year":"2024","unstructured":"Tartof SY, Aliabadi N, Goodwin G, Slezak J, Hong V, Ackerson B, et al. Estimated vaccine effectiveness for respiratory syncytial virus-related lower respiratory tract disease. JAMA Netw Open. 2024;7(12):e2450832.","journal-title":"JAMA Netw Open"},{"issue":"10462","key":"693_CR57","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S0140-6736(24)01738-0","volume":"404","author":"AB Payne","year":"2024","unstructured":"Payne AB, Watts JA, Mitchell PK, Dascomb K, Irving SA, Klein NP, et al. Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October 2023, to March, 2024: a test-negative design analysis. Lancet. 2024;404(10462):1547\u201359.","journal-title":"Lancet"},{"issue":"16","key":"693_CR58","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","volume":"388","author":"B Kampmann","year":"2023","unstructured":"Kampmann B, Madhi SA, Munjal I, Sim\u00f5es EAF, Pahud BA, Llapur C, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388(16):1451\u201364.","journal-title":"N Engl J Med"}],"container-title":["Israel Journal of Health Policy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13584-025-00693-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13584-025-00693-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13584-025-00693-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T12:05:31Z","timestamp":1749643531000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijhpr.biomedcentral.com\/articles\/10.1186\/s13584-025-00693-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["693"],"URL":"https:\/\/doi.org\/10.1186\/s13584-025-00693-5","relation":{},"ISSN":["2045-4015"],"issn-type":[{"value":"2045-4015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,11]]},"assertion":[{"value":"15 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This evaluation was reviewed by the National Helsinki Committee for Human Medical Research of the Israel Ministry of Health; it was determined to be part of the Ministry of Health\u2019s professional activity, which is presented in an anonymized and aggregated form, and as such, does not require an ethical committee\u2019s approval or informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}